Teleflex Incorporated announced on December 10, 2025 that it has entered into a definitive agreement to sell its Teleflex Medical OEM business to private‑equity firms Montagu and Kohlberg for $1.5 billion in cash. The OEM unit, which supplies custom‑engineered interventional catheter components and sub‑assemblies, will become an independent contract developer and manufacturer after the transaction closes in the second half of 2026.
The sale is part of a broader divestiture package that also includes the Acute Care and Interventional Urology businesses, which were sold to Intersurgical Ltd. for $530 million. Together, the three divestitures total $2.03 billion, with $1.8 billion expected after tax. Teleflex plans to use the proceeds to fund a $1 billion share‑repurchase program, reduce debt, and support future growth initiatives in its core Vascular Access, Interventional, and Surgical segments.
The OEM business had been a drag on Teleflex’s profitability, with profits falling double‑digits in the first nine months of 2025 compared with 2024. By divesting this unit, Teleflex removes a low‑margin, low‑growth line that no longer aligns with its strategic focus on high‑growth medical technology markets.
CEO Liam Kelly said the divestiture “establishes Teleflex as a more focused medical technologies leader” and positions the company for future growth. Greg Stotts, who has led the OEM unit for years, will become the CEO of the newly independent company under Montagu and Kohlberg.
Investors responded positively to the announcement, citing the strategic portfolio optimization, the sizable cash proceeds, and the planned share‑repurchase program as key drivers of confidence in Teleflex’s future prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.